Berkshire requires a 25–50% discount to intrinsic value before buying.
Buffett Quality Checklist
✓ROE >15% consistently (≥7 of last 10 years)
✓Free cash flow positive (≥8 of last 10 years)
✓Conservative leverage — Debt/Equity below 1
✗Revenue growing at CAGR >5%
✓EPS growing at CAGR >5%
10-Year Financial History — SEC EDGAR 10-K Filings
Year▲
Revenue▲
Net Income▲
FCF▲
Owner Earnings▲
ROE▲
Net Margin▲
LT Debt▲
Cash▲
2016
$25.7B
$14.2B
$3.6B
$14.3B
111.5%
55.3%
$13.9B
$4.6B
2017
$25.6B
$10.2B
$4.7B
$10.2B
66.5%
40.0%
$13.9B
$1.3B
2018
$25.4B
$7.0B
$8.2B
$7.0B
47.1%
27.5%
$13.0B
$1.3B
2019
$25.1B
-$1.3B
$7.6B
-$1.3B
-20.8%
-5.1%
$28.0B
$2.1B
2020
$26.2B
$4.5B
$8.2B
$4.5B
157.3%
17.1%
$29.5B
$4.9B
2021
$26.0B
$2.5B
$8.2B
$2.5B
—
9.5%
$28.0B
$4.5B
2022
$25.1B
$5.8B
$8.1B
$5.8B
—
23.0%
$26.7B
$4.0B
2023
$24.5B
$8.1B
$9.1B
$8.2B
—
33.2%
$26.2B
$3.7B
2024
$24.0B
$11.3B
$8.6B
$11.4B
—
46.9%
$24.9B
$3.1B
2025
$23.3B
$6.9B
$9.1B
$7.0B
—
29.8%
$25.7B
$4.5B
Warren & Charlie
Buffett / Munger — quality, moat & valuation
ALTRIA GROUP, INC. (MO) — Investment Memo
🐂 The Bull Case (Warren's voice)
The beauty of a business that sells a habit is that the customer does the marketing for you.
The Ultimate Pricing Power: Altria possesses the rare ability to raise prices faster than volume declines. This is a classic toll bridge—the users are captive, the demand is inelastic, and the cost to maintain the moat is negligible.
Regulatory Protectionism: While the FDA is a headache, it is also a shield. The barrier to entry for a new combustible cigarette brand is effectively infinite. The government has inadvertently created a legal oligopoly.
Cash Flow Primacy: Forget the accounting noise and the "hallucination" of ROE. This business generates staggering FCF with almost zero requirement for capital reinvestment. It is a pure cash-extraction play.
Attractive Entry: This becomes a Berkshire-grade asset only when the market prices it as a "melting ice cube" with zero future growth. We want it at a price where the dividend yield alone provides a massive cushion against the slow decay of the core product.
🐻 The Bear Case (Charlie inverts)
"If you're betting on the competence of management to 'pivot' a dying habit, you're a fool."
The "Regulatory Guillotine": The permanent impairment scenario isn't a slow decline, but a sudden, structural blow—such as a federal ban on menthols or a mandate for "non-addictive" nicotine levels. This would collapse the pricing power overnight.
The Substitution Gap: The core business is leaking. If the transition to smoke-free products (NGP) continues to be characterized by expensive failures (JUUL, Cronos) rather than organic adoption, the revenue leak becomes a flood.
Capital Allocation Malpractice: Management has proven a chronic tendency to "chase the shiny object" with shareholder cash. They are gambling with the house money on speculative bets to fix a problem that may be structurally unsolvable.
Most Likely Path: A steady, irreversible decline in volume accelerated by a "lollapalooza" effect of regulatory pressure and societal stigma, occurring over the next 5–10 years.
💰 Valuation & Margin of Safety
The DCF treats this as a slow-motion liquidation. We must be colder still.
Intrinsic value estimate: $45.68 per share.
25% margin of safety entry: $34.26(Conservative).
50% margin of safety entry: $22.84(Buffett's ideal).
Current Status: Based on the DCF, the business is dangerously priced if trading anywhere near $45. Unless the stock is trading in the $30s, we are paying for a growth story that doesn't exist and a management team we don't trust.
Verdict: PASS
The intrinsic value of $45.68 offers no meaningful cushion against structural regulatory risks. While the cash flow is seductive, the history of catastrophic capital allocation makes the moat feel like a trap. We will not pay a fair price for a business in permanent retreat.
Other Analyst Views· Lynch · Damodaran
Research Notes· Money Model · Moat · Financials · Management
Data sourced from SEC EDGAR XBRL filings (10-K only). For educational purposes — not investment advice.